C21 may protect the heart from chemotherapy toxicity

2016-09-27

The first study showing a cardioprotective effect of the AT2-receptor agonist, C21, in cancer treatment.

The first study showing a cardioprotective effect of the AT2-receptor agonist, C21, in cancer treatment.


The anthracyclins are effective drugs for the treatment of breast cancer, but they also carry a risk for cardiotoxic side effects. At the recent European cardiology congress, Dr Necip Ermis and colleagues from Malatya, Turkey, presented an evaluation of possible cardioprotective effects of C21 on anthracycline-induced cardiotoxicity in rats. Histological analysis showed that damage to the cardiac myocytes was reduced following treatment with C21.

Dr Ermis: “ This is the first study showing a cardioprotective effect of the AT2-receptor agonist, C21, in anthracycline treated animals. The combination of C21 with an angiotensin receptor blocker looks particularly promising. Trials in cancer patients ought to be initiated to document these effects clinically.”

Vicore Pharma has submitted a patent application related to cardio protection of C21 in connection with cancer treatment and will analyze the business conditions for continuing the development within this area. It is too early to foresee the commercial potential for C21 and cardioprotective effects in cancer treatments and the indication is not a priority for Vicore Pharma.

Link to abstract

For more information, please contact:

Anders Ljunggren, Senior Adviser
Tel: 070-657 95 69 eller e-mail: anders.ljunggren@vicorepharma.com

Per Jansson, CEO
Tel: 0709-17 47 46 eller e-mail: per.jansson@vicorepharma.com

About Vicore PharmaVicore Pharma is 100% owned by Vicore Pharma Holding, a Nasdaq First North Stockholm listed investment and management company. Vicore Pharma develops drugs targeting stimulation of the AT2 Receptor (AT2R) in the Renin-Angiotensin-System (RAS). The company vision is to establish a new class of small molecule drugs to allieviate chronic inflammatory and fibrotic diseases through selective agonism with AT2R. The company’s lead compound, C21, is currently in clinical Phase I following numerous peer review publications with positive outcome in preclinical efficacy studies. For further information, please refer to www.vicorepharma.com

Vicore Pharma Holdings share is listen on Nasdaq Stockholm, First North under ticker VICO. The company's certified adviser is Redeye AB. Stockholm, Sweden

  • Press release in html format